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Risk assessment of patients with non–ST-elevation acute
coronary syndromes (NSTEACS) plays an important role
in determining the prognosis. This enhances the cost-
effectiveness of patient care by allowing evidence-based
treatments (such as antiplatelet, anti-thrombotic, and revas-
cularization therapies) to be targeted at the patients who are
most likely to benefit from their use. The clinical history,
examination findings, electrocardiographic (ECG) changes,
and cardiac troponin levels are all crucial factors in assessing
risk (1–8). In patients with NSTEACS, troponin levels
predict the likelihood of benefit from treatment with low-
molecular-weight heparins, glycoprotein IIb/IIIa antago-
nists, and early revascularization (9–11).
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Risk assessment should be considered a dynamic process,
and refractory ischemia or evidence of ongoing (including
silent) ischemia on ECG monitoring should mandate early
angiography. Risk assessment may be enhanced by deter-
mining the number and severity of flow-limiting coronary
artery stenoses and the presence or absence of left ventric-
ular (LV) impairment.
There has been extensive research into the roles of
inflammation and inflammatory markers in NSTEACS.
Elevated levels of C-reactive protein and serum amyloid-A
were first reported in patients with NSTEACS in the early
1990s (12,13). The levels of high-sensitivity C-reactive
protein (hsCRP), interleukin-6 and, more recently, CD-40
ligand (which has prothrombotic effects) have been shown
to have independent prognostic significance (14). Elevated
levels of other inflammatory markers, such as adhesion mole-
cules (13), interleukin-7 (15), and matrix-metalloproteinases
(including pregnancy-associated plasma protein-A) (16)
have also been observed in patients with NSTEACS.
Conversely, levels of the anti-inflammatory cytokine,
interleukin-10, have been shown to be reduced in patients
with NSTEACS, and patients with higher levels of
interleukin-10 suffer fewer events during follow-up (17).
There have been no prospective trials of therapies aimed at
modulating the levels of these markers. Neither the Amer-
ican College of Cardiology/American Heart Association (1)
nor the European Society of Cardiology treatment guide-
lines (18) for NSTEACS currently recommend measure-
ment of inflammatory marker levels (18).
In this issue of the Journal, the Fragmin and Fast
Revascularisation During Instability in Coronary Artery
Disease (FRISC-II) investigators (19) expand upon their
previous work on markers of myocardial necrosis and
inflammation in patients with NSTEACS (20) with a
report describing an association between amino-terminal
brain natriuretic pro-peptide (NT-proBNP) levels and two-
year mortality. When patients were classified into tertiles
based on their NT-proBNP levels at admission, the risk
ratios for two-year mortality in the upper tertile (NT-
proBNP levels of 905 ng/l in men and 1,345 ng/l in
women) were 4.1 (95% confidence interval [CI] 2.4 to 7.2)
in the conservative treatment limb and 3.5 (95% CI 1.8 to
6.8) in the invasive treatment limb, as compared with
patients in the lowest tertile. Invasive treatment resulted in
absolute mortality reductions of 3.6% (risk ratio 0.67, 95%
CI 0.41 to 1.10) in the upper tertile and 0.6% (risk ratio
0.78, 95% CI 0.39 to 1.57) in the lowest and middle
NT-proBNP tertiles. This association was independent of
other prognostic markers such as interleukin-6 and troponin
T levels. The largest mortality reduction achieved by inva-
sive treatment (7.3% absolute) was in patients who were in
the upper NT-proBNP tertile and who also had
interleukin-6 levels of 5 mg/l. Troponin T levels were not
an independent predictor of mortality.
There are three classes of natriuretic peptides: atrial
natriuretic peptide (ANP) (first identified in 1981) (21),
brain natriuretic peptide (BNP) (first identified in porcine
brains in 1988) (22), and the more recently described
C-type natriuretic peptide, which is derived from endothe-
lial cells and cells expressed in the nervous system. The
release of natriuretic peptides from myocardial cells is
provoked by a variety of stimuli, including hypoxia, isch-
emia, exercise, increased wall stress, and dilation of the atria
and/or ventricles; the latter may be due to transient (includ-
ing silent) ischemia, stunning, or hibernation. Other cardiac
pathologies, such as hypertensive heart disease, atrial fibril-
lation, and valvular heart disease, are also associated with
elevation of natriuretic peptide levels (19,23). In normal
individuals, the blood levels of BNP (amino acids 77 to 108)
and NT-proBNP (amino acids 1 to 76) are similar and
significantly lower than the ANP levels (24). The cost of
natriuretic peptide assays is approximately US$20.
The release of ANP, BNP, and NT-proBNP is markedly
increased in patients with heart failure (HF), whether it is
due to diastolic dysfunction or to systolic LV dysfunction,
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and thus natriuretic peptide levels cannot be used to
differentiate between these two causes of HF. Natriuretic
peptide levels have prognostic significance in patients with
chronic HF, including those who are receiving combination
beta-blocker and angiotensin-converting enzyme inhibitor
therapy and those with asymptomatic or minimally symp-
tomatic LV dysfunction (25). Natriuretic peptide levels
predict the response to treatment and the likelihood of
readmission, and may be used for titration of pharmacologic
therapies (26). Elevated BNP levels have also been used to
identify patients at increased risk of sudden death (27).
Atrial natriuretic peptide, BNP, and NT-proBNP levels
have been shown to have similar correlations with both the
extent of LV dysfunction and the risk of late mortality in
patients with ST-elevation acute coronary syndromes (28).
The Treat Angina With Aggrastat and Determine Cost
of Therapy with an Invasive or Conservative Strategy-
Thrombolysis in Myocardial Infarction 18 (TACTICS-
TIMI-18) investigators (29) have previously reported an
association between BNP levels at admission and six-month
mortality in patients with NSTEACS. In patients with
NSTEACS in the Orbofiban in Patients with Unstable
Coronary Syndromes-Thrombolysis in Myocardial Infarc-
tion 16 (OPUS-TIMI-16) trial, the levels of troponin I,
hsCRP, and BNP at admission were independent predictors
of the composite six-month end point of death, myocardial
infarction (MI), or congestive HF, a finding validated in a
cohort of 1,635 patients from the TACTICS-TIMI-18
trial (30).
In previous studies of patients with NSTEACS,
NT-proBNP levels have been shown to be an independent
prognostic factor for mortality (31–33). In an observational
study of 755 patients, the risk ratios for death in patients
with NT-proBNP levels in the second, third, and fourth
quartiles (vs. the lowest quartile) were 4.2, 10.7, and 26.6,
respectively (31). In another study of 609 patients (all of
whom underwent echocardiography), NT-proBNP levels
measured on day 3 provided prognostic information inde-
pendently of the Killip class and LV ejection fraction (32).
In the Platelet Receptor Inhibition in Ischemic Syndrome
Management (PRISM) study, NT-proBNP levels measured
at 72 h were the only independent predictor of the com-
posite 30-day end point of death and infarction, whereas
troponin and hsCRP levels were not predictive (33).
The findings of the current FRISC-II substudy indicate
that NT-proBNP levels at admission predict the benefit of
revascularization and add prognostic information to that
obtained from clinical and ECG data and from markers of
myocyte necrosis and inflammation. However, in
TACTICS-TIMI-18, revascularization did not benefit pa-
tients with elevated BNP levels (80 ng/l) at admission
(34). There are various possible explanations for this observa-
tion, which appears to conflict with the FRISC-II findings.
First, in patients with NSTEACS, the rise in NT-
proBNP levels may be greater than the rise in BNP levels.
Only 19% of patients in TACTICS-TIMI-18 had BNP
levels of 80 ng/l, whereas at least 30% of patients in
FRISC-II had NT-proBNP levels of 1,000 ng/l, and the
distribution was less skewed.
Second, the patient characteristics of the TACTICS-
TIMI-18 and FRISC-II populations differed somewhat in
that the TACTICS-TIMI-18 patients had a higher inci-
dence of previous MI (39% vs. 23%). In both studies,
natriuretic peptide levels were related to the angiographic
severity of coronary artery disease. In TACTICS-TIMI-18,
the incidence of left main or triple-vessel disease (reported
by the core laboratory) (31) was 22%, whereas in FRISC-II
it was 34%, and the rate of surgical revascularization in
patients randomized to undergo invasive treatment was
lower in TACTICS-TIMI-18 than in FRISC-II (21% vs.
35%).
Third, early revascularization did not reduce the
overall mortality rate in TACTICS-TIMI-18 (3.3% vs.
3.5% with conservative treatment), although it did reduce
the incidence of recurrent ischemic events. It is therefore
unlikely that revascularization would have reduced mortality
in the subgroup of patients with elevated BNP levels.
However, the nonsignificant 13% relative reduction in
six-month mortality seen in TACTICS-TIMI-18 patients
with BNP levels of80 ng/ml (odds ratio 0.87, 95% CI 0.4
to 1.9) is not inconsistent with the 41% relative reduction in
two-year mortality seen in patients in the highest tertile of
NT-proBNP levels in FRISC-II.
The FRISC-II investigators chose interleukin-6, rather
than hsCRP, as the inflammatory marker for inclusion in
their multivariate models, because they had previously found
that interleukin-6 was superior to hsCRP in predicting risk
in the same FRISC-II population (19). When NT-proBNP
was added to the multivariate model of two-year mortality
predictors, the interleukin-6 level was no longer a significant
predictor (95% CI 0.92 to 3.09). Considering that hsCRP
testing is more readily available and there is more extensive
literature on its use (14), it would have been interesting to
evaluate the prognostic information added by NT-proBNP
levels to that obtained from hsCRP levels.
What are the pathophysiologic mechanisms that make
elevated natriuretic peptides levels adverse risk factors in
patients with NSTEACS? These peptides have salutary
effects on the cardiovascular system, including diuretic and
natriuretic effects, blood pressure reduction, inhibition of
the angiotensin system, and modulation of endothelial
function. Their independent association with risk may be
due to multiple mechanisms.
First, elevation of natriuretic peptide levels may result
from acute LV dysfunction caused by acute or old myocyte
necrosis, and the risk associated with elevated levels could
therefore be related to the effect of LV impairment on
mortality (including sudden death) or to new or progressive
HF.
Second, elevation of natriuretic peptide levels may result
from acute myocardial stretch caused by ischemia without
myocyte necrosis, and the risk associated with elevated levels
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could therefore be related to the extent of ischemia and the
consequent risks of future infarction and arrhythmia (pos-
sibly sudden cardiac death). Brain natriuretic peptide levels
have been shown to rise after transient myocardial ischemia
resulting from inflation of an angioplasty balloon (35). In
TACTICS-TIMI-18, 6.6% of patients without elevated
troponin I levels (i.e., with levels of 1.0 g/l) had elevated
BNP levels. The TACTICS-TIMI-18 and FRISC-II in-
vestigators found that natriuretic peptide levels were asso-
ciated with the extent of angiographic coronary disease, and
in these trials BNP/NT-proBNP levels were higher in
patients with ST depression. In view of previous data
showing correlations between BNP levels and the size of the
ischemic area measured by nuclear stress imaging (36), it is
surprising that elevated natriuretic peptide levels were not
predictors of recurrent ischemic events or MI in
TACTICS-TIMI-18 and FRISC-II. In FRISC-II, the
only predictor of reinfarction was an elevated troponin level,
and it is not clear why natriuretic peptide levels were not
found to be a predictor, whereas in the PRISM study, there
was a correlation between higher NT-proBNP levels and
the risk of MI (p  0.01) (33). It would enhance our
understanding of the associations between natriuretic pep-
tides and ischemia to know how well natriuretic peptide
levels correlated with the extent of ischemia, documented
electrocardiographically, in TACTICS-TIMI-18 and
FRISC-II.
Third, interpretation of natriuretic peptide levels in the
setting of NSTEACS may be confounded by the fact that
elevations of these markers can result from various patho-
physiologic mechanisms (or possibly even a combination of
different mechanisms) unrelated to acute myocardial isch-
emia or necrosis causing LV dysfunction. Interpretation of
natriuretic peptide levels may also be confounded by age,
gender, or severe renal impairment.
The natriuretic peptides themselves may also have ther-
apeutic applications. Natriuretic peptide receptor-A knock-
out mice have been shown to develop hypertension with
marked cardiac hypertrophy and fibrosis (37). In BNP
knockout mice, ventricular pressure overload leads to in-
creased cardiac fibrosis because the production and release
of BNP may inhibit collagen accumulation (38). Exog-
enously administered BNP has been shown to limit the
infarct size in a rat heart model of acute MI (34). Intra-
venous nesiritide (recombinant human BNP) has been
shown to have beneficial hemodynamic effects, reducing
pulmonary capillary wedge pressure in patients with acute
HF (39).
To enhance risk stratification, measurement of BNP or
NT-proBNP levels should be performed at admission in
patients presenting with NSTEACS. However, the optimal
timing of measurement has not yet been defined, and
different prognostic information may be obtained if levels
are measured at a later stage. The treatment implications of
elevated natriuretic peptide levels may include more appro-
priate targeting of revascularization and aggressive anti-
platelet (33) and antithrombotic therapies. It is yet to be
determined whether therapies directed at cardiac neurohor-
monal activation, such as angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers, should be used
in all patients with NSTEACS and elevated natriuretic
peptide levels.
Future trials should be designed to evaluate targeted
therapies based on elevations in the levels of one or more
markers occurring in conjunction with the pathophysiologic
mechanisms of necrosis, inflammation, or ischemia causing
myocardial stretch. Such trials will provide further insights
into the interaction between troponins, inflammatory mark-
ers, and natriuretic peptides in the pathogenesis and dy-
namic risk assessment of NSTEACS.
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